Indication
as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation

Medicine details

Medicine name:
blinatumomab (Blincyto)
SMC ID:
SMC2148
Pharmaceutical company
Amgen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated submission
Status
Advice due date:
08 April 2019
SMC meeting date:
05 March 2019